Ect2 Function in Lung Adenocarcinoma Initiation and Maintenance

Ect2 在肺腺癌发生和维持中的功能

基本信息

  • 批准号:
    9095722
  • 负责人:
  • 金额:
    $ 21.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-04-01 至 2018-03-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Epithelial cell transforming sequence 2 (Ect2) has been identified as an oncogene in human tumors. Ect2 is sufficient to drive transformation in fibroblasts, is overexpressed in a variety of tumors and is required for transformed growth of tumor cells. However, the specific mechanism(s) by which Ect2 exerts its oncogenic activity in tumors are currently unknown. Our preliminary studies indicate that: 1) Ect2 GEF activity and nuclear localization are required for transformation, 2) Ect2 co-localizes with the nucleolar protein Upstream Binding Factor 1 (UBF1) and regulates ribosomal RNA (rRNA) synthesis, and 3) genetic loss of Ect2 inhibits Kras/p53-mediated lung tumorigenesis in vivo and growth of lung tumor initiating cells (TICs) ex vivo. Thus, we hypothesize that: 1) Ect2-mediated rRNA transcription is important for lung adenocarcinoma (LADC) transformation and 2) Ect2 drives Kras/p53-mediated LADC formation by maintaining a lung TIC phenotype in vivo. Two specific aims are proposed to test these hypotheses. In Aim 1 we will determine the role of Ect2 regulation of rRNA transcription in LADC transformation and in Aim 2 we will determine the role of Ect2 in the tumorigenicity of LADC TICs in vivo. Completion of these aims will provide insight into the role of Ect2 in the tumorigenic behavior of TICs, enhance our understanding of the initiating events in K-ras-mediated lung tumorigenesis and how a key step in ribosome biosynthesis, rRNA synthesis, may be regulated in tumor cells to promote the transformed phenotype.
 描述(由申请人提供):上皮细胞转化序列2(Ect 2)已被鉴定为人类肿瘤中的癌基因。Ect 2足以驱动成纤维细胞的转化,在多种肿瘤中过表达,并且是肿瘤细胞转化生长所需的。然而,Ect 2在肿瘤中发挥其致癌活性的具体机制目前尚不清楚。我们的初步研究表明:1)Ect 2 GEF活性和核定位是转化所必需的,2)Ect 2与核仁蛋白上游结合因子1(UBF 1)共定位并调节核糖体RNA(rRNA)合成,3)Ect 2的遗传缺失抑制体内Kras/p53介导的肺肿瘤发生和体外肺肿瘤起始细胞(TIC)的生长。因此,我们假设:1)Ect 2介导的rRNA转录对于肺腺癌(LADC)转化是重要的,并且2)Ect 2通过在体内维持肺TIC表型来驱动Kras/p53介导的LADC形成。提出了两个具体的目标来测试这些假设。在目标1中,我们将确定Ect 2在LADC转化中调节rRNA转录的作用,在目标2中,我们将确定Ect 2在体内LADC TIC致瘤性中的作用。这些目标的完成将提供深入了解Ect 2在TIC的致瘤行为中的作用,增强我们对K-ras介导的肺肿瘤发生中的起始事件以及核糖体生物合成的关键步骤rRNA合成如何在肿瘤细胞中受到调控以促进转化表型的理解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Verline Justilien其他文献

Verline Justilien的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Assessing The Impact of Heparanase and NDST2 Expression on Non-Small Cell Lung Adenocarcinoma Cell Motility
评估乙酰肝素酶和 NDST2 表达对非小细胞肺腺癌细胞运动的影响
  • 批准号:
    449570
  • 财政年份:
    2020
  • 资助金额:
    $ 21.95万
  • 项目类别:
    Studentship Programs
Analysis of cancer metastasis and invasion mechanism using a new lung adenocarcinoma cell line.
使用新的肺​​腺癌细胞系分析癌症转移和侵袭机制。
  • 批准号:
    16K10689
  • 财政年份:
    2016
  • 资助金额:
    $ 21.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Acquisition strategy of tumor-specific markers using established micropapillary pattern pulmonary adenocarcinoma cell line
使用已建立的微乳头模式肺腺癌细胞系获取肿瘤特异性标志物的策略
  • 批准号:
    26460441
  • 财政年份:
    2014
  • 资助金额:
    $ 21.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The antibetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo.
抗生素药物二甲双胍在体外和体内抑制食管腺癌细胞增殖。
  • 批准号:
    25860540
  • 财政年份:
    2013
  • 资助金额:
    $ 21.95万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
The cell permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferations and can be used as the molecular targeting dru
细胞通透肽抑制胰腺导管腺癌细胞增殖,可作为分子靶向药物
  • 批准号:
    25461969
  • 财政年份:
    2013
  • 资助金额:
    $ 21.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Basic Research for elucidation of chemo-resistance in mucinous adenocarcinoma cell.
阐明粘液腺癌细胞化疗耐药性的基础研究。
  • 批准号:
    22791532
  • 财政年份:
    2010
  • 资助金额:
    $ 21.95万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
TAS::75 0849::TAS IN THIS PHASE I SBIR THE BREAST CANCER ADENOCARCINOMA CELL LI
TAS::75 0849::TAS 在这一阶段 I SBIR 乳腺癌腺癌细胞 LI
  • 批准号:
    8164743
  • 财政年份:
    2010
  • 资助金额:
    $ 21.95万
  • 项目类别:
Role of Endothelin-1 in osteoblastic bone metastasis produced by a human lung adenocarcinoma cell line
Endothelin-1 在人肺腺癌细胞系产生的成骨细胞骨转移中的作用
  • 批准号:
    19790127
  • 财政年份:
    2007
  • 资助金额:
    $ 21.95万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
CONNEXIN 43 EXPRESSION IN ADENOCARCINOMA CELL LINE
连接蛋白 43 在腺癌细胞系中的表达
  • 批准号:
    6972483
  • 财政年份:
    2004
  • 资助金额:
    $ 21.95万
  • 项目类别:
The mechanisms of highly metastetic capasity in highly metastatic subpopulations of lung adenocarcinoma cell line and these clinical applications
肺腺癌细胞系高转移亚群的高转移能力机制及临床应用
  • 批准号:
    15590831
  • 财政年份:
    2003
  • 资助金额:
    $ 21.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了